Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2021						Print
																Related Pages
										Return to Main Menu
Table 49. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT):1 Reporting Areas, 20192

Tuberculosis cases and percentages by completion of tuberculosis therapy and reporting area.
Reporting area
Total cases3
Therapy ≤1 year indicated4
Therapy >1 year indicated5No.
Completed therapy
Did not complete therapy
No.
Completed therapy≤1 year
>1 year
Duration unknownNo.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)United States6
7,694
7,189
6,460
(89.9)
387
(5.4)
16
(0.2)
326
(4.5)
505
474
(93.9)Alabama
73
71
66
(93.0)
3
(4.2)
0
(0.0)
2
(2.8)
2
2
(100.0)Alaska
54
52
47
(90.4)
1
(1.9)
0
(0.0)
4
(7.7)
2
2
(100.0)Arizona
126
116
109
(94.0)
6
(5.2)
0
(0.0)
1
(0.9)
10
8
(80.0)Arkansas
59
56
49
(87.5)
2
(3.6)
0
(0.0)
5
(8.9)
3
3
(100.0)California
1,793
1,696
1,499
(88.4)
110
(6.5)
1
(0.1)
86
(5.1)
97
89
(91.8)Colorado
60
55
52
(94.5)
1
(1.8)
2
(3.6)
0
(0.0)
5
5
(100.0)Connecticut
55
53
49
(92.5)
4
(7.5)
0
(0.0)
0
(0.0)
2
2
(100.0)Delaware
16
16
13
(81.3)
1
(6.3)
0
(0.0)
2
(12.5)
0
0
...District of Columbia
22
22
19
(86.4)
0
(0.0)
0
(0.0)
3
(13.6)
0
0
...Florida
487
467
455
(97.4)
12
(2.6)
0
(0.0)
0
(0.0)
20
19
(95.0)Georgia
261
251
226
(90.0)
15
(6.0)
0
(0.0)
10
(4.0)
10
8
(80.0)Hawaii
92
86
79
(91.9)
4
(4.7)
0
(0.0)
3
(3.5)
6
6
(100.0)Idaho
6
6
6
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
0
...Illinois
264
242
225
(93.0)
10
(4.1)
1
(0.4)
6
(2.5)
22
22
(100.0)Indiana
99
90
85
(94.4)
4
(4.4)
0
(0.0)
1
(1.1)
9
9
(100.0)Iowa
45
39
30
(76.9)
4
(10.3)
0
(0.0)
5
(12.8)
6
6
(100.0)Kansas
29
26
26
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
3
3
(100.0)Kentucky
54
50
48
(96.0)
1
(2.0)
0
(0.0)
1
(2.0)
4
4
(100.0)Louisiana
80
76
56
(73.7)
8
(10.5)
0
(0.0)
12
(15.8)
4
3
(75.0)Maine
16
16
14
(87.5)
1
(6.3)
0
(0.0)
1
(6.3)
0
0
...Maryland
192
176
147
(83.5)
12
(6.8)
6
(3.4)
11
(6.3)
16
15
(93.8)Massachusetts
158
142
121
(85.2)
14
(9.9)
0
(0.0)
7
(4.9)
16
16
(100.0)Michigan
119
105
100
(95.2)
4
(3.8)
0
(0.0)
1
(1.0)
14
13
(92.9)Minnesota
139
114
102
(89.5)
8
(7.0)
0
(0.0)
4
(3.5)
25
24
(96.0)Mississippi
54
49
44
(89.8)
1
(2.0)
0
(0.0)
4
(8.2)
5
5
(100.0)Missouri
65
62
49
(79.0)
2
(3.2)
1
(1.6)
10
(16.1)
3
2
(66.7)Montana
2
1
0
(0.0)
0
(0.0)
1
(100.0)
0
(0.0)
1
0
(0.0)Nebraska
15
13
11
(84.6)
1
(7.7)
0
(0.0)
1
(7.7)
2
1
(50.0)Nevada
45
41
40
(97.6)
1
(2.4)
0
(0.0)
0
(0.0)
4
4
(100.0)New Hampshire
6
6
6
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
0
...New Jersey
271
251
233
(92.8)
12
(4.8)
0
(0.0)
6
(2.4)
20
20
(100.0)New Mexico
37
37
33
(89.2)
1
(2.7)
0
(0.0)
3
(8.1)
0
0
...New York State7
146
137
121
(88.3)
10
(7.3)
0
(0.0)
6
(4.4)
9
9
(100.0)New York City
491
458
413
(90.2)
26
(5.7)
0
(0.0)
19
(4.1)
33
32
(97.0)North Carolina
170
165
148
(89.7)
5
(3.0)
0
(0.0)
12
(7.3)
5
5
(100.0)North Dakota
16
12
9
(75.0)
1
(8.3)
0
(0.0)
2
(16.7)
4
4
(100.0)Ohio
130
127
109
(85.8)
12
(9.4)
0
(0.0)
6
(4.7)
3
3
(100.0)Oklahoma
55
52
43
(82.7)
5
(9.6)
0
(0.0)
4
(7.7)
3
2
(66.7)Oregon
67
62
60
(96.8)
1
(1.6)
0
(0.0)
1
(1.6)
5
5
(100.0)Pennsylvania
158
144
129
(89.6)
9
(6.3)
0
(0.0)
6
(4.2)
14
13
(92.9)Rhode Island
12
11
8
(72.7)
3
(27.3)
0
(0.0)
0
(0.0)
1
1
(100.0)South Carolina
66
60
57
(95.0)
1
(1.7)
0
(0.0)
2
(3.3)
6
5
(83.3)South Dakota
15
12
11
(91.7)
0
(0.0)
0
(0.0)
1
(8.3)
3
3
(100.0)Tennessee
119
112
109
(97.3)
1
(0.9)
0
(0.0)
2
(1.8)
7
7
(100.0)Texas
1,003
940
814
(86.6)
60
(6.4)
4
(0.4)
62
(6.6)
63
58
(92.1)Utah
23
22
21
(95.5)
0
(0.0)
0
(0.0)
1
(4.5)
1
1
(100.0)Vermont
4
4
3
(75.0)
0
(0.0)
0
(0.0)
1
(25.0)
0
0
...Virginia
172
161
151
(93.8)
5
(3.1)
0
(0.0)
5
(3.1)
11
11
(100.0)Washington
202
180
169
(93.9)
4
(2.2)
0
(0.0)
7
(3.9)
22
20
(90.9)West Virginia
6
6
6
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
0
...Wisconsin
44
40
39
(97.5)
1
(2.5)
0
(0.0)
0
(0.0)
4
4
(100.0)Wyoming
1
1
1
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
0
...American Samoa
1
1
0
(0.0)
0
(0.0)
0
(0.0)
1
(100.0)
0
0
...Federated States of Micronesia
81
76
66
(86.8)
0
(0.0)
1
(1.3)
9
(11.8)
5
5
(100.0)Guam
74
73
65
(89.0)
4
(5.5)
0
(0.0)
4
(5.5)
1
1
(100.0)Republic of the Marshall Islands
215
213
174
(81.7)
1
(0.5)
0
(0.0)
38
(17.8)
2
1
(50.0)Northern Mariana Islands
44
44
41
(93.2)
1
(2.3)
0
(0.0)
2
(4.5)
0
0
...Puerto Rico
30
26
26
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
4
4
(100.0)Republic of Palau
6
6
6
(100.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
0
...U.S. Virgin Islands
1
1
0
(0.0)
0
(0.0)
0
(0.0)
1
(100.0)
0
0
...Show More1Excludes persons who died or moved out of the country within one year of initiating therapy2Most recent year for which data are complete.3Persons alive at diagnosis with an initial regimen of one or more drugs prescribed.4Excludes persons with an initial isolate resistant to rifampin; persons with bone and joint disease, meningeal disease, or disease of the central nervous system; or persons < 15 years of age with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen.5Persons with an initial isolate resistant to rifampin; persons with bone and joint disease, meningeal disease, or disease of the central nervous system; or persons <15 years of age with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen.6American Samoa, Federated States of Micronesia, Guam, Republic of the Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands are not included in the U.S. totals and percentages.7Excludes New York City.
**Note:**
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes.Table Printing Tips
							
					
							Last Reviewed:  November 29, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue